What Do Noninferiority Trials Say About Coronary Stents?

Affiliations

Free article

Editorial

John A Bittl. JACC Cardiovasc Interv. 2017.

Free article

. 2017 Feb 13;10(3):265-267.

doi: 10.1016/j.jcin.2016.11.041. Epub 2017 Jan 18.

¹ Interventional Cardiology Group, Munroe Regional Medical Center, Ocala, Florida. Electronic address: jabittl@mac.com.

No abstract available

Keywords: Bayesian analysis; clinical trials; percutaneous coronary intervention; p value; randomized controlled trials; stent polymers.

Comment on

5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
Yeh RW, Silber S, Chen L, Chen S, Hiremath S, Neumann FJ, Qiao S, Saito S, Xu B, Yang Y, Mauri L. Yeh RW, et al. JACC Cardiovasc Interv. 2017 Feb 13;10(3):247-254. doi: 10.1016/j.jcin.2016.11.004. Epub 2017 Jan 18. JACC Cardiovasc Interv. 2017. PMID: 28109872
Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B, Christiansen EH, Bøtker HE, Hansen HS, Ravkilde J, Thuesen L, Aarøe J, Villadsen AB, Terkelsen CJ, Krusell LR, Maeng M, Kristensen SD, Veien KT, Hansen KN, Junker A, Madsen M, Andersen SL, Jensen SE, Jensen LO; SORT OUT VI Investigators. Raungaard B, et al. JACC Cardiovasc Interv. 2017 Feb 13;10(3):255-264. doi: 10.1016/j.jcin.2016.11.007. Epub 2017 Jan 18. JACC Cardiovasc Interv. 2017. PMID: 28109874 Clinical Trial.